Mayo Clinic
Dr. Mesa on Ruxolitinib in Myelofibrosis
Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the use of JAK2 inhibitors in patients with myelo…
A quote for you...
Powered By Optimism Quotes
Dr. Mesa on Late-Stage Trials in Myelofibrosis
Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, describes three phase II and phase III trials in myelofibro…
A quote for you...
Powered By Optimism Quotes
Dr. Mesa on the Evolving Role of JAK2 Inhibitors in Myelofibrosis
Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the use of JAK2 inhibitors in patients with myelofibrosis. For more information regarding myelofibrosis and other hematologic malignancies, visit: www.onclive.com
A quote for you...
Powered By Optimism Quotes
One Thousand Patients With Primary Myelofibrosis: the Mayo Clinic Experience
Dr. Ayalew Tefferi, Consultant in the Department of Hematology at Mayo Clinic in Rochester, MN, discusses his article appearing in the January 2012 issue of Mayo Clinic Proceedings describing the Mayo Clinic experience with 1000 patients who have primary myelofibrosis and providing context for the design and interpretation of clinical… Continue reading
Myeloproliferative Neoplasms 2011 – Mayo Clinic
Hematologist Ruben Mesa, MD, Chair, Division of Hematology and Oncology at Mayo Clinic in Arizona, provides an update on Myeloproliferative Neoplasms
A quote for you...
Powered By Optimism Quotes
Myelofibrosis and Bone Marrow Transplant – Mayo Clinic
Ruben Mesa, MD and Veena Fauble, MD, Mayo Clinic hematologists, discuss bone marrow transplant as a treatment option for patients diagnosed with myelofibrosis.
A quote for you...
Powered By Optimism Quotes
Survival Data for Patients Younger Than 60 With Primary Myleofibrosis–Mayo Clinic Proceedings
Dr. Ayalew Tefferi, Professor of Hematology and Medicine at Mayo Clinic in Rochester, MN, discusses the findings of the largest ever study with the most mature data currently available of patients with primary myelofibrosis younger than 60 years. These 176 patients were followed up for a median of 8 years… Continue reading
Study Results: Ruxolitinib and Myelofibrosis – Mayo Clinic
Dr. Ruben Mesa, MD, hematologist at Mayo Clinic in Arizona, discusses study findings which show that Ruxolitinib helps reduce symptoms of myelofibrosis.
A quote for you...
Powered By Optimism Quotes
Myelofibrosis Study
Two janus kinase (JAK) inhibitors are substantially improving treatment of myelofibrosis in patients, say Mayo Clinic researchers who are presenting results of several clinical trials at the 52nd annual meeting of the American Society of Hematology (ASH) Dec. 4–7 in Orlando. Their findings suggest that both drugs, CYT387 and TG101348,… Continue reading
Myelofibrosis 2012 Update – Mayo Clinic
Ruben Mesa, MD, hematologist at Mayo Clinic in Arizona, discusses the updates in the treatment and management of myelofibrosis.
Related Blogs
A quote for you...
Powered By Optimism Quotes